CARTESIAN THERAPEUTICS INC
Silver Spring, MD · Founded 2007 · CIK 0001453687 · Biotech · Public
mRNA-engineered cell therapies for autoimmune diseases
cartesiantherapeutics.com →- Grants
- $11M
- 10 awards
- Sector median: 1
- Raised
- $446M
- 15 Form D · Jul 2024
- 27 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 39
- 8 granted · 31 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2009201120132015201720192021202320252027
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $15,000,006 | |
| Private capital raised· 1 of 2 same day | Form D · SEC | $22,000,000 | |
| Private capital raised· 2 of 2 same day | Form D · SEC | $3,500,000 | |
| Private capital raised | Form D · SEC | $5,292,702 | |
| Private capital raised | Form D · SEC | $6,000,000 | |
| Private capital raised | Form D · SEC | $4,450,000 | |
| Private capital raised | Form D · SEC | $5,942,306 | |
| Private capital raised | Form D · SEC | $37,400,000 | |
| Private capital raised | Form D · SEC | $4,999,984 | |
| Private capital raised | Form D · SEC | $50,000,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Transient anti-BCMA CAR T-cells for Treatment of Multiple Myeloma | $299,042 | |
| Private capital raised | Form D · SEC | $5,752,495 | |
| Private capital raised | Form D · SEC | $70,000,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Autologous T-cells Expressing a Chimeric Antigen Receptor Directed to B-Cell Maturation Antigen (BCMA) in patients with Generalized Myasthenia Gravis (MG) | $835,858 | |
| Federal grant | Department of Health and Human Services · Phase II · Autologous T-cells Expressing a Chimeric Antigen Receptor Directed to B-Cell Maturation Antigen (BCMA) in patients with Generalized Myasthenia Gravis (MG) | $1,990,216 | |
| Federal grant | Department of Health and Human Services · Phase II · Phase 1/2 Clinical Study of Humanized Anti-BCMA CAR T Cells in Relapsed/Refractory Multiple Myeloma (MM) | $988,226 | |
| Private capital raised | Form D · SEC | $25,000,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Phase 1/2 Clinical Study of Humanized Anti-BCMA CAR T Cells in Relapsed/Refractory Multiple Myeloma (MM) | $988,226 | |
| Federal grant | Department of Health and Human Services · Phase II · Phase 1/2a Clinical Study of Descartes-30 in Acute Respiratory Distress Syndrome | $998,742 | |
| Federal grant | Department of Health and Human Services · Phase II · Autologous T-cells Expressing a Chimeric Antigen Receptor Directed to B-Cell Maturation Antigen (BCMA) in patients with Generalized Myasthenia Gravis (MG) | $1,154,358 | |
| Federal grant | Department of Health and Human Services · Phase II · Phase 1/2a Clinical Study of Descartes-30 in Acute Respiratory Distress Syndrome | $999,491 | |
| Private capital raised | Form D · SEC | $60,250,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Manufacturing RNA-based CAR T cells to combat autoantibody-associated autoimmune disorders (AAAD) | $1,496,118 | |
| Private capital raised | Form D · SEC | $130,023,000 | |
| Federal grant | Department of Health and Human Services · Phase II · Manufacturing RNA-based CAR T cells to combat autoantibody-associated autoimmune disorders (AAAD) | $1,496,118 |
Federal grant · SBIR/STTRForm D · SECPress
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2774 | Arsenal Biosciences | — | $579M |
| 2775 | Invivyd, Inc. | — | $489M |
| 2776 | Recursion Pharmaceuticals, LLC | — | $466M |
| 2777 | CARTESIAN THERAPEUTICS INC | — | $446M |
| 2778 | Genetic Networks, LLC | — | — |
| 2779 | FLUIDFORM INC | — | — |
| 2780 | Tentarix | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Press
Cartesian Therapeutics Announces New Employment Inducement GrantsGlobeNewswire
Founders & Team
- David AbrahamExecutive Officer
- Goran AndoDirector
- Timothy BarabeDirector
- Robert BratzlerDirector · Executive Officer
- Carsten BrunnDirector · Executive Officer
- Werner CautreelsDirector · Executive Officer
- Douglas ColeDirector
- Carrie CoxDirector
- Bradford DahmsExecutive Officer
- Blaine DavisExecutive Officer
- Nishan de SilvaDirector
- Nishan De SilvaDirector
- Cole DouglasDirector
- Emily EnglishExecutive Officer
- Omid FarokhzadDirector
- Carl GordonDirector
- Peter HuttDirector
- Chris JewellExecutive Officer
- Lloyd JohnstonExecutive Officer
- Murat KalayogluDirector
- Edwin Kania, Jr.Director
- Peter KellerExecutive Officer
- Takashi KishimotoExecutive Officer
- Elona KoganExecutive Officer
- Metin KurtogluExecutive Officer
- Robert LangerDirector
- Robert Langer, Jr.Director
- Kemal MalikDirector
- Milos MiljkovicExecutive Officer
- Scott MyersDirector
- Amir NashatDirector
- Aymeric SallinDirector
- Earl SandsExecutive Officer
- Alison SchecterExecutive Officer
- Leysan ShaydullinaDirector
- George SiberDirector
- David SiewersExecutive Officer
- Michael SingerDirector
- Stephen SmolinksiExecutive Officer
- Stephen SmolinskiExecutive Officer
- Timothy SpringerDirector
- Yuriy UdaltsovDirector
- Patrick ZennerDirector
Patents
- Formulations And Doses Of Pegylated Uricaseapplication
- Engineered Cells Secreting Therapeutic Enzymesgranted
- Formulations And Doses Of Pegylated Uricasegranted
- Methods Related To Administering Immunosuppressants And Non-allergenic Antigens To Reduce Or Prevent Anaphylaxisgranted
- Methods Providing A Therapeutic Macromolecule And Synthetic Nanocarriers Comprising Immunosuppressant Locally And Concomitantly To Reduce Both Type 1 And Type IV Hypersensitivitygranted
- Methods Related To Administering Immunosuppressants And Therapeutic Macromolecules At A Reduced Pharmacodynamically Effective Doseapplication
- Methods And Compositions Related To Synthetic Nanocarriers With Rapamycin In A Stable, Super-saturated Stateapplication
- Methods And Compositions Related To Combined Treatment With Anti-inflammatories And Synthetic Nanocarriers Comprising An Immunosuppressantapplication
- Formulations And Doses Of Pegylated Uricaseapplication
- Formulations And Doses Of Pegylated Uricaseapplication
- Methods And Compositions Related To Combined Treatment With Anti-inflammatories And Synthetic Nanocarriers Comprising An Immunosuppressantgranted
- Multiprotein-engineered Cells Secreting A Multispecific Antibodyapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.